Cost-effectiveness of vasopressin in the treatment of septic shock: insights from a European societal perspective

Key Points

• The aim is to evaluate the cost-effectiveness of vasopressin as a second-line treatment for septic shock.
• Cost-effectiveness analysis from a societal perspective
• Evaluation of early intervention versus standard care
• Comparison of vasopressin with traditional vasopressors
• Vasopressin is cost-effective when started early in septic shock treatment
• Supports early vasopressor use according to clinical guidelines
• Highlights significant economic benefits alongside improved patient outcomes